Dier Mardi's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed Oct 14, 2021
- Accession no.
- 0001209191-21-060504
- Filed
- Oct 14, 2021
- Trade date
- Oct 12-14, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $552.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dier MardiCIK 0001574591 | Officer (CFO & Executive Vice President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 12, 2021 | Common Stock | SSaleDisposed | −3,477 | $82.79 | −$287,860.83 | 42,023 | Direct | |
| Oct 14, 2021 | Common Stock | SSaleDisposed | −3,261 | $81.16F3 | −$264,662.76 | 38,762 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.55 to $81.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.